XKRX200780
Market cap26mUSD
Dec 27, Last price
4,680.00KRW
1D
4.42%
1Q
-6.96%
Jan 2017
-77.84%
IPO
-59.42%
Name
BCWorldPharm Co Ltd
Chart & Performance
P/E
14.99
P/S
0.53
EPS
312.11
Div Yield, %
1.37%
Shrs. gr., 5y
-0.05%
Rev. gr., 5y
6.51%
Revenues
75.11b
+3.31%
Net income
2.63b
+836.31%
CFO
10.94b
+58.91%
Dividend
Dec 27, 2023100 KRW/sh
Profile
BCWORLD PHARM. Co., Ltd. operates as a pharmaceutical company in South Korea. The company provides products in various therapeutic areas comprising musculoskeletal system, digestive system, circulatory machine, central nervous system, adrenocorticosteroids, narcotic analgesics, erectile dysfunction treatment, wellbeing injection, diuretic, antitussive expectorant, vaginitis treatment, anti-tuberculosis drugs, anti-emetic, antiviral drugs, antibiotic, anti-malignant tumor drugs, antifungal agent, antihistamines, antidote, and antipyretic/analgesic/anti-inflammatory. BCWORLD PHARM. Co., Ltd. was founded in 1980 and is headquartered in Seongnam-si, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 75,110,699 3.31% | 72,702,522 17.11% | 62,079,357 8.85% | ||||||
Cost of revenue | 53,017,206 | 66,297,469 | 56,071,890 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 22,093,493 | 6,405,053 | 6,007,467 | ||||||
NOPBT Margin | 29.41% | 8.81% | 9.68% | ||||||
Operating Taxes | (1,686,176) | (1,582,690) | 42,057 | ||||||
Tax Rate | 0.70% | ||||||||
NOPAT | 23,779,669 | 7,987,742 | 5,965,410 | ||||||
Net income | 2,633,791 836.31% | 281,295 -115.26% | (1,843,085) 16.65% | ||||||
Dividends | (542,732) | (853,856) | (853,856) | ||||||
Dividend yield | 1.00% | 1.18% | 0.63% | ||||||
Proceeds from repurchase of equity | 32,950,791 | ||||||||
BB yield | -45.65% | ||||||||
| Debt | |||||||||
Debt current | 79,845,663 | 72,930,139 | 45,202,127 | ||||||
Long-term debt | 12,616,576 | 21,324,771 | 43,818,640 | ||||||
Deferred revenue | 3,300,000 | ||||||||
Other long-term liabilities | 370 | 154,871 | (200) | ||||||
Net debt | 79,512,385 | 84,834,859 | 80,761,830 | ||||||
| Cash flow | |||||||||
Cash from operating activities | 10,937,647 | 6,883,047 | (619,833) | ||||||
CAPEX | (2,576,918) | (6,438,602) | (18,810,684) | ||||||
Cash from investing activities | (3,764,316) | (6,677,590) | (17,689,847) | ||||||
Cash from financing activities | (4,248,191) | 1,072,557 | 10,336,717 | ||||||
FCF | 27,889,505 | 8,005,129 | (4,963,327) | ||||||
| Balance | |||||||||
Cash | 11,165,599 | 8,057,941 | 4,502,522 | ||||||
Long term investments | 1,784,255 | 1,362,110 | 3,756,415 | ||||||
Excess cash | 9,194,319 | 5,784,925 | 5,154,969 | ||||||
Stockholders' equity | 46,500,386 | 44,150,808 | 45,471,616 | ||||||
Invested Capital | 162,515,682 | 165,937,552 | 166,547,788 | ||||||
ROIC | 14.48% | 4.80% | 3.65% | ||||||
ROCE | 12.87% | 3.73% | 3.56% | ||||||
| EV | |||||||||
Common stock shares outstanding | 8,439 | 8,522 | 8,539 | ||||||
Price | 6,460.00 -23.73% | 8,470.00 -46.56% | 15,850.00 -32.84% | ||||||
Market cap | 54,513,130 -24.48% | 72,182,924 -46.66% | 135,336,255 -32.61% | ||||||
EV | 132,251,983 | 154,985,733 | 214,287,554 | ||||||
EBITDA | 29,563,023 | 13,668,085 | 11,590,790 | ||||||
EV/EBITDA | 4.47 | 11.34 | 18.49 | ||||||
Interest | 5,234,000 | 3,791,585 | 2,168,879 | ||||||
Interest/NOPBT | 23.69% | 59.20% | 36.10% | ||||||